Download McCormick Place Chicago, IL, USA

HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Your day-by-day guide to ASCO
30 May - 3 June 2008
McCormick Place
Chicago, IL, USA
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Contents
Congress details
2
Dining
3
Safety
4
Congress site plan
6
Floor plans
8
Key
11
Saturday 31 May
12
Sunday 1 June
14
Monday 2 June
17
Tuesday 3 June
20
Hotels
22
Map
23
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Congress details
Congress venue
McCormick Place
2301 South Lake Shore Drive
Chicago, IL 60616, USA
Tel: 312 791 7000; Fax: 312 791 6543
Congress registration
Location: Lakeside Center, Hall E, McCormick Place
Friday 30 May: Onsite registration opens (including self-registration)
Tuesday 3 June: Onsite registration closes
Congress dates and opening hours
2
Friday 30 May
13:00-18:00
Saturday 31 May
08:00-18:00
Sunday 1 June
08:00-18:00
Monday 2 June
08:00-18:00
Tuesday 3 June
08:00-13:00
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Dining
Recommended restaurants
Blue Water Grill (American Contemporary)
520 North Dearborn Street at Grand Avenue, Chicago, IL 60610
Tel: 312 777 1400
Capital Grille (American Steakhouse)
633 North St Clair Street, Chicago, IL 60611
Tel: 312 337 9400
Catch 35 (Seafood)
35 West Wacker Drive, Chicago, IL 60601
Tel: 312 346 3500
Coco Pazzo (Italian)
300 West Hubbard Street, Chicago, IL 60610
Tel: 312 836 0900
Everest Restaurant (American Contemporary)
440 South La Salle Street, 40th Floor, Chicago, IL 60605
Tel: 312 663 8920
McCormick & Schmick’s (Seafood)
1 East Wacker Drive, Chicago, IL 60601
Tel: 312 923 7226
Morton’s (Steak and Seafood)
65 East Wacker Place, Chicago, IL 60601
Tel: 312 201 0410
N9NE Steak House (American Steakhouse)
440 West Randolph Street, Chicago, IL 60606
Tel: 312 575 9900
Ruth’s Chris Steak House (American Steakhouse)
431 North Dearborn Street, Chicago, IL 60610
Tel: 312 321 2725
Santorini (Greek)
800 West Adams Street, Chicago, IL 60661
Tel: 312 829 8820
Smith & Wollensky (American Steakhouse)
318 North State Street, Chicago, IL 60610
Tel: 312 670 9900
The Palm (Steak, Seafood and Italian)
323 East Wacker Drive, Chicago IL 60601
Tel: 312 616 1000
3
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Safety
Safety tips
On leaving the congress site you are advised to remove your ASCO
name badge or any Roche identity insignia
Keep jewellery or accessories to a minimum and do not display
cameras or bags that can draw attention
Keep your wallet or precious belongings in your inside front pocket or
wear your handbag across your shoulders
Sightsee on well-lit, well-travelled streets and passages either with a
colleague or in a group
Important telephone numbers
Emergency services (Police, Ambulance, Fire): 911
Non-emergency services (Police and City Services): 311
Yellow Cab Chicago: 312 8294 222
Chicago Office of Tourism: 312 744 2400
4
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
5
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
16/5/08
Congress site plan
Lakeside Center
(East Building)
LE V
LE
LE
LE
VE
VE
VE
EL
4
LAKESIDE
BALLROOM
E354
L3
Halls D
Hall E
L2
L1
Office
1a
LE
LE
North
Building
VE
VE
VE
L3
L2
L1
SK
YB
RID
s
R o o m 45 1
E 45 0s
m
o
R o 35 3
E 35 0s
m
o
o
R
27 2
E 25 0-
ms
Roo -5 05
S5 0 1 s
m
o
o
R -4 0 6
S4 0 1
EL 3
LE V 4
EL
LEV
GE
s
ES
LAK
LE
nd D2
LEVEL 2
Roche bus
transfer gate: 38
Arie Crown
Theater
Restaurant
HOR
E DR
IVE
ms
R o o 6 - 4 27
N42
ms
Roo 6-231
N22
ms
Roo 6-14 0
N12
2
d C2
nd B
1 an
B1 a
alls C
H
r
Halls
o
f
CK
level
TRA
ance
AD
Entr
O
C2
R
d
n
IL
a
RA
s C1
Hall
TRA
ME
HYATT REGENCY
McCORMICK PLACE
HOTEL
LEV
GR
EL
AN
2.5
DC
ON
CO
UR
SE
LEVEL 2.5
Food Court/
Restaurant
Business Center
METRA Entrance
LEVEL 2
Restaurants
MA
IN
RT
TH
LU
ER
KI N
.D
JR
G,
R IV
LEV
EXISTING
GARAGE STRUCTURE
& CONFERENCE CENTER
CE
6
E
RM
LEV
LEV
LEV
AK
RO
AD
LEV
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
South
Building
Vista
Room
S406
A2
d
1 an
LEVE L
LE V E L
0
ls A
S10
Hal
om
allro
B
nd
Gra
3
2.5
LEVE L
1
SK
YB
RI
D
G
ms
R o o1 - 1 0 6
S10
476
-W
470
W
s
om
Ro
E
LEVEL 2.5
Food Court/
Restaurant
IVE
West
Building
196
LE V
LE V
R
LE V
LE V
LE V
D
EL
5
EL
4
EL
3
EL
2
EL
1
n
rde
75
Ga
W3
op
t
s
f
om
o
m
o
r
o
l
l
Ro
o
Ba
gR
UE
nd
etin
EN
Gra
AV
Me
;
2
A
F
F1,
IAN
lls
IND
Ha
s
om
g
etin
Me
Ro
-W
175
sW
m
o
Ro
LEVEL 2
Food Court/
Restaurant
Business Center
Gift Shops
7
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Floor plans
Level 4
Meeting Rooms (E450–E451)
Level 3
Exhibition Halls
Meeting Rooms (E350–E354)
Arie Crown Balcony
Level 2
Exhibition Halls
Meeting Rooms (E250–E272)
Arie Crown Theater
Arie Crown Theater
Roche bus
transfer
gate: 38
Level 1
Offices
Lakeside Center
Level 4
Meeting Rooms (N426–N427)
Level 3
Exhibition Halls
Level 2
Meeting Rooms (N226–N231)
Level 1
Exhibition Halls
Meeting Rooms (N126–N140)
North Building
8
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Level 5
Meeting Rooms (S501–S505)
Level 4
Vista Room (S406)
Meeting Rooms (S401–S405)
Level 3
Exhibition Halls
Grand Concourse
Level 2
Food Court/Restaurant
Shops & Services
Metra Trains
Level 1
Grand Ballroom (S100)
Meeting Rooms (S101–S106)
South Building
Level 5
Rooftop Garden
Level 4
Meeting Rooms
Level 3
Ballroom
Exhibition Hall
Level 2
Food Court/
Restaurant
Shops & Services
Level 1
Central Transportation Center
Meeting Rooms
West Building
9
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
10
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Key
Key to symbols used throughout the planner
A Avastin
H Herceptin
M MabThera
T Tarceva
X Xeloda
11
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Saturday
31 May
GENERAL POSTER SESSION
Time: 08:00-12:00
Venue: S Hall A1
Genitourinary cancer
A
A
Efficacy and safety of first-line bevacizumab (BEV) plus
interferon-␣2a (IFN) in patients (pts) ⭓65 years with
metastatic renal cell carcinoma (mRCC) (E Bajetta;
Poster 4D, Abstract 5095)
Costs of managing side effects in the treatment of first line
metastatic renal cell carcinoma (mRCC) in Germany,
France, and UK: Bevacizumab (BEV) + interferon alpha-2a
(IFN) compared with sunitinib (G Mickisch; Poster 6H,
Abstract 5110)
ORAL ABSTRACT PRESENTATION SESSION
Time: 15:00-18:00
Venue: E Hall D1
Gastrointestinal (colorectal) cancer
A
Initial safety report of NSABP C-08, a randomized phase III
study of modified 5-fluorouracil (5-FU)/leucovorin (LCV)
and oxaliplatin (OX) (mFOLFOX6) with or without
bevacizumab (bev) in the adjuvant treatment of patients
with stage II/III colon cancer (CJ Allegra; Abstract 4006)
Time: 15:15-15:30
A
X
Randomized phase III study of capecitabine, oxaliplatin, and
bevacizumab with or without cetuximab in advanced
colorectal cancer (ACC), the CAIRO2 study of the Dutch
Colorectal Cancer Group (DCCG) (CJ Punt;
Abstract LBA4011)
Time: 16:45-17:00
12
A Avastin
X
Xeloda
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Saturday
31 May
ORAL ABSTRACT PRESENTATION SESSION
Time: 15:00-18:00
Venue: W375e
Genitourinary cancer (testes, kidney and bladder)
A
Update on AVOREN trial in metastatic renal cell carcinoma
(mRCC): Efficacy and safety in subgroups of patients (pts)
and pharmacokinetic (PK) analysis (BJ Escudier;
Abstract 5025)
Time: 16:15-16:30
A Avastin
13
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Sunday
1 June
ORAL ABSTRACT PRESENTATION SESSION
Time: 08:00-11:00
Venue: E354b
Lymphoma
M
Improved outcome of elderly patients with poor-prognosis
diffuse large B-cell lymphoma (DLBCL) after dose-dense
rituximab: results of the DENSE-R-CHOP-14 trial of the
German High-Grade Non-Hodgkin Lymphoma Study
Group (DSHNHL) (M Pfreundschuh; Abstract 8508)
Time: 08:45-09:00
ORAL ABSTRACT PRESENTATION SESSION
Time: 08:00-11:00
Venue: E Hall D1
Breast cancer - metastatic
A
Randomized, double-blind, placebo-controlled, phase III
study of bevacizumab with docetaxel or docetaxel with
placebo as first-line therapy for patients with locally
recurrent or metastatic breast cancer (mBC): AVADO
(D Miles; Abstract LBA1011)
Time: 08:30-08:45
H
Randomized study comparing efficacy/toxicity of
monotherapy trastuzumab followed by monotherapy
docetaxel at progression, and combination trastuzumab/
docetaxel as first-line chemotherapy in HER2-neu positive,
metastatic breast cancer (MBC) (HERTAX study)
(M Bontenbal; Abstract 1014)
Time: 09:00-09:15
14
M MabThera
A Avastin
H Herceptin
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Sunday
1 June
H
A randomized study of lapatinib alone or in combination
with trastuzumab in heavily pretreated HER2+ metastatic
breast cancer progressing on trastuzumab therapy
(J O’Shaughnessy; Abstract 1015)
Time: 09:15-09:30
POSTER DISCUSSION SESSION
Time: 08:00-12:00 [discussion 11:00-12:00]
Venue: E450a [E Hall D2]
Gastrointestinal (colorectal) cancer
A
A
X
A
X
X
Final efficacy results for bevacizumab plus standard first-line
chemotherapies in patients with metastatic colorectal cancer:
First BEAT (SR Berry; Poster 12, Abstract 4025)
International multi-centre randomised Phase II/III study of
Capecitabine (Cap), bevacizumab (Bev) and mitomycin C
(MMC) as first-line treatment for metastatic colorectal
cancer (mCRC): Final safety analysis of the AGITG MAX
trial (T Price; Poster 16, Abstract 4029)
Activity of the combination of bevacizumab (Bev) with
capecitabine/irinotecan (CapIri/Bev) or capecitabine/
oxaliplatin (CapOx/Bev) in advanced colorectal cancer
(ACRC): A randomized phase II study of the AIO Colorectal
Study Group (AIO trial 0604) (AC Reinacher-Schick;
Poster 17, Abstract 4030)
Randomized trial comparing cetuximab plus XELIRI versus
cetuximab plus XELOX as first line treatment of patients
with metastatic colorectal cancer (mCRC): A study of the
German AIO CRC study group (V Heinemann; Poster 20,
Abstract 4033)
H Herceptin
A Avastin
X
Xeloda
15
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Sunday
1 June
GENERAL POSTER SESSION
Time: 14:00-18:00
Venue: S Hall A1
Lung cancer - metastatic
T
A
A
T
A
T
16
MERIT: analysis of differential gene expression in patients
(pts) with advanced non-small-cell lung cancer (NSCLC)
treated with erlotinib (P Delmar; Poster 42A, Abstract 8046)
Safety of first-line bevacizumab-based therapy with
concomitant cardiovascular or anticoagulation medication
in advanced or recurrent non-squamous non-small cell lung
cancer (NSCLC) in MO19390 (SAiL) (F Griesinger;
Poster 42D, Abstract 8049)
Effects of diagnostic method and surgery on safety of firstline bevacizumab plus chemotherapy in advanced or
recurrent non-squamous non-small cell lung cancer
(NSCLC): MO19390 (SAiL) (C-M Tsai; Poster 43E,
Abstract 8058)
Efficacy of erlotinib in patients (pts) with advanced nonsmall-cell lung cancer (NSCLC) relative to clinical
characteristics: subset analyses from the TRUST study
(SG Allan; Poster 46D, Abstract 8081)
Safety of bevacizumab-based therapy as first-line treatment
of patients with advanced or recurrent non-squamous nonsmall cell lung cancer (NSCLC): MO19390 (SAiL)
(E Dansin; Poster 46H, Abstract 8085)
A phase II study of first-line erlotinib in patients (pts) with
stage IIIb/IV non-small-cell lung cancer (NSCLC) including
dose escalation to toxicity in current and former smokers
(C/FS) (B Besse; Poster 51H, Abstract 8111)
T
Tarceva
A Avastin
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Monday
2 June
GENERAL POSTER SESSION
Time: 08:00-12:00
Venue: S Hall A1
Gastrointestinal (colorectal) cancer
X
A
X
A
Capecitabine and oxaliplatin as first-line treatment in
patients with metastatic colorectal cancer (MCRC): A
pooled analysis of randomized phase II-III trials
(R Porschen; Poster 3E, Abstract 4055)
Waterfall plot analysis of XELOX or XELIRI with cetuximab
or bevacizumab in patients with advanced colorectal cancer
(ACRC): Combined analysis of two randomized first-line
phase II trials of the AIO CRC study group (D Arnold;
Poster 5E, Abstract 4067)
The safety of long-term bevacizumab use: Results from the
BRiTE observational cohort study (OCS) (D Purdie;
Poster 14G, Abstract 4103)
POSTER DISCUSSION SESSION
Time: 08:00-12:00 [discussion 12:00-13:00]
Venue: W375e lobby [W375d]
Lung cancer - metastatic
T
T
FAST-ACT: A phase II randomized double-blind trial of
sequential erlotinib and chemotherapy as first-line treatment
in patients (pts) with stage IIIB/IV non-small cell lung
cancer (NSCLC) (JS Lee; Poster 12, Abstract 8031)
Intermittent erlotinib (ERL) schedules in combination with
pemetrexed (PEM): Phase I schedules designed to achieve
pharmacodynamic separation (AM Davies; Poster 13,
Abstract 8032)
X
Xeloda
A Avastin
T
Tarceva
17
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Monday
2 June
GENERAL POSTER SESSION
Time: 14:00-18:00
Venue: S Hall A1
Breast cancer - local-regional and adjuvant therapy
X
First report of the European Cooperative Trial in Operable
Breast Cancer II (ECTO II): Effects of primary chemoendocrine therapy on local-regional disease in ER-positive
breast cancer (M Zambetti; Poster 11G, Abstract 588)
GENERAL POSTER SESSION
Time: 14:00-18:00
Venue: S Hall A1
Breast cancer - metastatic
X
H
A
X
18
Randomized trial of first-line docetaxel + capecitabine (XT)
versus docetaxel + epirubicin (ET) for metastatic breast
cancer (MBC): Efficacy results of ERASME-4/CAPEDOCEPIDOC (T Bachelot; Poster 24G, Abstract 1049)
Observational Demetra study: Survival of metastatic breast
carcinoma patients after treatment with trastuzumab
(S Ménard; Poster 31G, Abstract 1062)
A phase II trial investigating if bevacizumab in combination
with hormone therapy will reverse acquired estrogen
independence in metastatic breast cancer patients
(C Falkson; Poster 34B, Abstract 1074)
A novel capecitabine dosing schedule combined with
bevacizumab is safe and active in patients with metastatic
breast cancer: A phase II study (T Traina; Poster 40H,
Abstract 1101)
X
Xeloda
H Herceptin
A Avastin
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Monday
2 June
ORAL ABSTRACT PRESENTATION SESSION
Time: 15:00-18:00
Venue: E Hall D2
Gastrointestinal (noncolorectal) cancer
A
T
A randomized, double-blind, placebo (P) controlled,
multicenter phase III trial to evaluate the efficacy and safety
of adding bevacizumab (B) to erlotinib (E) and gemcitabine
(G) in patients (pts) with metastatic pancreatic cancer
(W Vervenne; Abstract 4507)
Time: 15:45-16:00
A Avastin
T
Tarceva
19
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Tuesday
3 June
POSTER DISCUSSION SESSION
Time: 08:00-12:00 [discussion 11:00-12:00]
Venue: E450b [E354a]
Breast cancer - metastatic
H
X
H
H
X
A
20
Capecitabine vs capecitabine vs + trastuzumab in patients
with HER2-positive metastatic breast cancer progressing
during trastuzumab treatment: the TBP phase III study
(GBG 26/BIG 3-05) (G Von Minckwitz; Poster 6,
Abstract 1025)
Results of a phase II trial of trastuzumab (H) and
pertuzumab (P) in patients (pts) with HER2-positive
metastatic breast cancer (MBC) who had progressed during
trastuzumab therapy (KA Gelmon; Poster 7, Abstract 1026)
A phase I study of trastuzumab-DM1 (T-DM1), a first-inclass HER2 antibody-drug conjugate (ADC), in patients (pts)
with advanced HER2+ breast cancer (BC) (M Beeram;
Poster 9, Abstract 1028)
Randomized, multicenter, phase III trial of docetaxel plus
epirubicin (ET) with or without capecitabine (X) as firstline therapy for stage IV breast cancer (BC) (M Mansutti;
Poster 15, Abstract 1034)
Independent review of E2100 progression-free survival
(PFS) with the addition of bevacizumab (B) to paclitaxel (P)
as initial chemotherapy for metastatic breast cancer (MBC)
(BJ Klencke; Poster 17, Abstract 1036)
H Herceptin
X
Xeloda
A Avastin
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Tuesday
3 June
POSTER DISCUSSION SESSION
Time: 08:00-12:00 [discussion 11:00-12:00]
Venue: S403 [S406 Vista Room]
Gastrointestinal (noncolorectal) cancer
H
HER2-positivity rates in advanced gastric cancer (GC):
results from a large international phase III trial (Y-J Bang;
Poster 14, Abstract 4526)
H Herceptin
21
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Hotels
Avenue Hotel Chicago
160 East Huron Street,
Chicago, IL 60611
Tel: 312 787 2900
www.avenuehotelchicago.com
Breakfast: Madison / Avenue
room, 13th floor, 06:30-10:30
Blackstone Chicago
636 South Michigan Avenue,
Chicago, IL 60605
Tel: 312 447 0955
www.marriott.com
Breakfast: Room Chicago,
06:30-09:00
Chicago City Centre Hotel
300 East Ohio Street,
Chicago, IL 60611
Tel: 312 787 6100
www.chicagocitycentrehotel.com
Breakfast: Restaurant 300 East,
06:30-10:30
Congress Plaza Hotel
520 South Michigan Avenue,
Chicago, IL 60605
Tel: 312 427 3800
www.congressplazahotel.com
Breakfast: Great Hall, 2nd floor,
06:30-10:00
22
Hilton Chicago
720 South Michigan Avenue,
Chicago, IL 60605
Tel: 312 922 4400
www.hilton.com
Breakfast: The Pavilion,
Mon-Fri 05:30-11:00;
Sat 05:30-12:00; Sun 05:30-14:00
Hyatt Regency McCormick Place
2233 South Martin Luther King
Drive, Chicago, IL 60616
Tel: 312 567 1234
www.mccormickplace.hyatt.com
Breakfast: Shor, Grand
Concourse, 06:30-11:00
Whitehall Hotel
105 East Delaware Place,
Chicago, IL 60611
Tel: 312 944 6300
www.thewhitehallhotel.com
Breakfast: Salon I–III, 2nd floor,
06:30-10:30
Wyndham Chicago
633 North St Clair Street,
Chicago, IL 60611
Tel: 312 573 0300
www.wyndham.com
Breakfast: Caliterra, 2nd floor,
06:30-11:00
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Map
N State st
Chicago
Downtown
W Division St
Whitehall
W Chicago Ave
Avenue
Wyndham
W Ontario
Chicago City Center
W Ohio
Navy Pier
Hyatt Regency
E Wacker D
r
W Wacker Dr
W Randolph St
Columbus Dr
Palmer House
W Jackson Blvd
Lake
Michigan
Congress Parkway
Congress Plaza
Blackstone
E Balbo Dr
Hilton
W Roosevelt Rd
rive
hore D
Lake S
S Michigan Ave
S State st
Hyatt Regency McCormick
S Martin
W Cermak Rd
McCormick Place
Dr
ng
Ki
er
Luth
23
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Notes
24
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Notes
25
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
Notes
26
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
16/5/08
HLR44722_ASCO_PocketPlanner:HLR42220_ASCO_PocketPlanner
F. Hoffmann-La Roche Ltd
CH-4070 Basel
Switzerland
16/5/08